Nonvertebral fracture risk reduction with nitrogen-containing bisphosphonates

Current Osteoporosis Reports

Volumn 6, Issue 3, 2008, Pages 89-94

  Hochberg, Marc C ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; IBANDRONIC ACID; PLACEBO; RISEDRONIC ACID; ZOLEDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; DRUG DERIVATIVE; ETIDRONIC ACID; IMIDAZOLE DERIVATIVE;

BONE DENSITY; BONE TURNOVER; CLAVICLE FRACTURE; CLINICAL TRIAL; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG MEGADOSE; FRAGILITY FRACTURE; HIP FRACTURE; HUMAN; HUMERUS FRACTURE; LEG FRACTURE; PELVIS FRACTURE; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRIMARY PREVENTION; REVIEW; RISK REDUCTION; SECONDARY PREVENTION; VERTEBRA FRACTURE; WRIST FRACTURE; CHEMISTRY; DOSE RESPONSE; DRUG EFFECT; FEMALE; FRACTURE; MALE; OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SPINE FRACTURE;

ALENDRONATE; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; ETIDRONIC ACID; FEMALE; FRACTURES, BONE; HUMANS; IMIDAZOLES; MALE; OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SPINAL FRACTURES;

EID: 55249092920     PISSN: 15441873     EISSN: 15442241     Source Type: Journal    
DOI: 10.1007/s11914-008-0016-6     Document Type: Review

References (42)

1. Consensus Development Conference: Diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 1993, 94:646-650.
2. Osteoporosis prevention, diagnosis, and therapy. NIH Consens Statement 2000, 17:1-45.
3. Chrischilles DA, Butler CD, Davis CS, et al.: A model of lifetime osteoporosis impact. Arch Intern Med 2001, 151:2026-2032.
4. Johnell O, Kanis JA, Oden A, et al.: Mortality after osteoporosis fractures. Osteoporos Int 2004, 15:38-42.
5. Seeley DG, Browner WS, Nevitt MC, et al.: Which fractures are associated with low appendicular bone mass in elderly women? The Study of Osteoporotic Fractures Research Group. Ann Intern Med 1991, 115:837-842.
6. Stone KL, Seeley DG, Lui LY, et al.: BMD at multiple sites and risk of fracture of multiple types: Long-term results from the Study of Osteoporotic Fractures. J Bone Miner Res 2003, 18:1947-1954.
7. MacLean C, Alexander A, Carter J, et al.: Comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Comparative Effectiveness Review No. 12. (Prepared by Southern California/RAND Evidence-Based Practice Center under contract no. 290-02-0003.) Agency for Healthcare Research and Quality. Available at: http://www.effectivehealthcare.ahrq.gov/reports/final.cfm. Accessed January 8, 2008.
8. MacLean C, Newberry S, Maglione M, et al.: Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med 2008, 148:197-213.
9. Cranney A, Wells G, Willan A, et al.: Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev 2002, 23:508-516.
10. Cranney A, Tugwell P, Adachi J, et al.: Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocr Rev 2002, 23:517-523.
11. Papapoulos SE, Quandt SA, Liberman UA, et al.: Metaanalysis of the efficacy of alendronate for the prevention of hip fractures in postmenopausal women. Osteoporos Int 2005, 16:468-474.
12. Stevenson M, Jones ML, De Nigris E, et al.: A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis. Health Technol Assess 2005, 9:1-160.
13. Nguyen ND, Eisman JA, Nguyen TV: Anti-hip fracture efficacy of bisphosphonates: A Bayesian analysis of clinical trials. J Bone Miner Res 2006, 21:340-349.
14. Boonen S, Laan RF, Barton IP, Watts NB: Effect of osteoporosis treatments on risk of non-vertebral fractures: Review and meta-analysis of intention-to-treat studies. Osteoporos Int 2005, 16:1291-1298.
15. Liberman UA, Hochberg MC, Geusens P, et al.: Hip and non-spine fracture risk reductions differ among antiresorptive agents: Evidence from randomized controlled trials. Int J Clin Pract 2006, 60:1394-1400.
16. Chesnut CH III, Skag A, Christiansen C, et al.: Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004, 19:1241-1249.
17. Recker R, Stakkestad JA, Chesnut CH 3rd, et al.: Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis. Bone 2004, 34:890-899.
18. Harris ST, Blumentals WA, Miller PD: Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: Results of a meta-analysis of phase III studies. Curr Med Res Opin 2008, 24:237-245.
19. Black DM, Delmas PD, Eastell R, et al.: Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007, 356:1809-1822.
20. Lyles KW, Colon-Emeric CS, Magaziner JS, et al.: Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007, 357:1799-1809.
21. Wells G, Cranney A, Peterson J, et al.: Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 2008, 23:CD001155.
22. Wells G, Cranney A, Peterson J, et al.: Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 2008, 23:CD004523.
23. Bucher HC, Guyatt GH, Griffith LE, Walter SD: The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 1997, 50:683-691.
24. Schnitzer T, Bone HG, Crepaldi G, et al.: Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging (Milano) 2000, 12:1-12.
25. Rizzoli R, Greenspan SL, Bone HG, et al.: Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis. J Bone Miner Res 2002, 17:1988-1996.
26. Brown JP, Kendler DL, McClung MR, et al.: The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int 2002, 71:103-111.
27. Harris ST, Watts NB, Li Z, et al.: Two-year efficacy and tolerability of risedronate once a week for the treatment of women with postmenopausal osteoporosis. Curr Med Res Opin 2004, 20:757-764.
28. Delmas PD, McClung MR, Zanchetta JR, et al.: Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis. Bone 2008, 42:36-42.
29. Delmas PD, Benhamou CL, Man Z, et al.: Monthly dosing of 75 mg risedronate on 2 consecutive days a month: Efficacy and safety results. Osteoporos Int 2008, 19:1039-1045.
30. Miller PD, McClung MR, Macovei L, et al.: Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from MOBILE study. J Bone Miner Res 2005, 20:1315-1322.
31. Reginster JY, Adami S, Lakatos P, et al.: Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2-year results from the MOBILE study. Ann Rheum Dis 2006, 65:654-661.
32. Delmas PD, Adami S, Strugala C, et al.: Intravenous ibandronate injections in postmenopausal women with osteoporosis: One-year results from the dosing intravenous administration study. Arthritis Rheum 2006, 54:1838-1846.
33. Eisman JA, Civitelli R, Adami S, et al.: Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study. J Rheumatol 2008, 35:488-497.
34. Papapoulos SE, Schimmer RC: Changes in bone remodeling and antifracture efficacy of intermittent bisphosphonate therapy: Implications from clinical studies with ibandronate. Ann Rheum Dis 2007, 66:853-858.
35. McAlister FA, Laupacis A, Wells GA, Sackett DL, for the Evidence-Based Medicine Working Group: Users' Guides to the Medical Literature: XIX. Applying clinical trial results B. Guidelines for determining whether a drug is exerting (more than) a class effect. JAMA 1999, 282: 1371-1377.
36. Hosking D, Adami S, Felsenberg D, et al.: Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: A randomized, placebo-controlled study. Curr Med Res Opin 2003, 19:383-394.
37. Rosen CJ, Hochberg MC, Bonnick SL, et al.: Treatment with once-weekly alendronate 70 mg compared with onceweekly risedronate 35 mg in women with postmenopausal osteoporosis: A randomized double-blind study. J Bone Miner Res 2005, 20:141-151.
38. Bonnick S, Saag KG, Kiel DP, et al.: Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years. J Clin Endocrinol Metab 2006, 91:2631-2637.
39. Miller PD, Epstein S, Sedarati F, Reginster JY: Oncemonthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: Results from the head-to-head MOTION study. Curr Med Res Opin 2008, 24:207-213.
40. Hochberg MC, Greenspan S, Wasnich RD, et al.: Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab 2002, 87:1586-1592.
41. Hochberg MC: The comparative efficacy of N-containing bisphosphonates as measured by fracture risk reduction [abstract]. Abstract submitted for 2008 Annual Meeting of the American Society for Bone and Mineral Research.
42. Miller PD: Non-vertebral fracture risk reduction with oral bisphosphonates: Challenges with interpreting clinical trial data. Curr Med Res Opin 2008, 24:107-119.